Abstract
Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.
| Original language | English |
|---|---|
| Pages (from-to) | 603-606 |
| Number of pages | 4 |
| Journal | International Journal of Oncology |
| Volume | 3 |
| Issue number | 4 |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2. / Abbate, I.; Guida, M.; Musci, M. D.; Casamassima, A.; Latorre, A.; Addabbo, L.; Dragone, C. D.; Cattedra, M.; Correale, M.; De Lena, M.
In: International Journal of Oncology, Vol. 3, No. 4, 1993, p. 603-606.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2
AU - Abbate, I.
AU - Guida, M.
AU - Musci, M. D.
AU - Casamassima, A.
AU - Latorre, A.
AU - Addabbo, L.
AU - Dragone, C. D.
AU - Cattedra, M.
AU - Correale, M.
AU - De Lena, M.
PY - 1993
Y1 - 1993
N2 - Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.
AB - Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.
UR - http://www.scopus.com/inward/record.url?scp=0027377979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027377979&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0027377979
VL - 3
SP - 603
EP - 606
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 4
ER -